Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Vista Pharmaceuticals Limited focuses on developing and commercializing specialty pharmaceuticals, primarily targeting niche markets in the healthcare sector. The company operates primarily in India and has a portfolio that includes generic and branded medications, but faces significant challenges due to recent revenue declines and negative margins.
Vista Pharmaceuticals generates revenue through the sale of generic and branded medications, leveraging its manufacturing capabilities in India to maintain competitive pricing. However, the company struggles with pricing pressure and market access, which has led to negative gross margins.
Regulatory approvals for new drug formulations
Market share changes in the Indian pharmaceutical sector
Pricing dynamics in generic drug markets
Partnerships or collaborations with larger pharmaceutical companies
Regulatory changes impacting drug approval processes
Technological disruption in drug development and manufacturing
Intense competition from generic drug manufacturers
Potential market entry of larger pharmaceutical companies
Negative operating cash flow impacting liquidity
High operational leverage leading to significant losses
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by GDP fluctuations.
Interest rates impact Vista's financing costs for R&D and operational expenses, which can exacerbate its current cash flow issues.
minimal - The company has a manageable debt-to-equity ratio of 0.27, indicating limited reliance on external financing.
value - Investors may be looking for turnaround opportunities given the low market cap and potential for recovery.
high - The stock has shown significant price fluctuations, evidenced by a 1-year return of -40.2%.
